friedreich’s ataxia

New York, New York, August,11, 2026 Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors, has announced...

BALA CYNWYD, Pennsylvania, April 30, 2026 Larimar Therapeutics, Inc. announced the publication of new cross-species research supporting the use...

Bala Cynwyd, Pa., September 29, 2025: Larimar Therapeutics announced positive new data from an ongoing long-term open-label study of...